Zacks: Analysts Anticipate Jazz Pharmaceuticals PLC (JAZZ) Will Announce Quarterly Sales of $461.36 Million

Analysts forecast that Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) will announce sales of $461.36 million for the current fiscal quarter, Zacks reports. Eight analysts have issued estimates for Jazz Pharmaceuticals’ earnings, with the highest sales estimate coming in at $490.40 million and the lowest estimate coming in at $449.47 million. Jazz Pharmaceuticals posted sales of $436.40 million during the same quarter last year, which would indicate a positive year over year growth rate of 5.7%. The business is expected to announce its next quarterly earnings results on Tuesday, February 26th.

On average, analysts expect that Jazz Pharmaceuticals will report full-year sales of $1.88 billion for the current financial year, with estimates ranging from $1.86 billion to $1.92 billion. For the next year, analysts anticipate that the firm will report sales of $2.07 billion, with estimates ranging from $1.99 billion to $2.19 billion. Zacks’ sales averages are a mean average based on a survey of analysts that cover Jazz Pharmaceuticals.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last announced its quarterly earnings results on Tuesday, November 6th. The specialty pharmaceutical company reported $3.58 earnings per share for the quarter, topping analysts’ consensus estimates of $3.32 by $0.26. The company had revenue of $469.37 million for the quarter, compared to analysts’ expectations of $482.64 million. Jazz Pharmaceuticals had a net margin of 28.09% and a return on equity of 24.92%. The business’s quarterly revenue was up 14.0% compared to the same quarter last year. During the same period last year, the firm posted $3.22 earnings per share.

JAZZ has been the topic of several research reports. Piper Jaffray Companies reaffirmed a “buy” rating and issued a $213.00 price objective on shares of Jazz Pharmaceuticals in a research report on Wednesday, August 8th. Cantor Fitzgerald set a $203.00 price objective on shares of Jazz Pharmaceuticals and gave the company a “buy” rating in a research report on Tuesday, August 7th. Stifel Nicolaus boosted their price objective on shares of Jazz Pharmaceuticals from $180.00 to $205.00 and gave the company a “buy” rating in a research report on Wednesday, August 8th. BMO Capital Markets boosted their price objective on shares of Jazz Pharmaceuticals from $201.00 to $206.00 and gave the company an “outperform” rating in a research report on Wednesday, August 8th. Finally, Seaport Global Securities reaffirmed a “buy” rating and issued a $207.00 price objective on shares of Jazz Pharmaceuticals in a research report on Thursday, August 9th. Five analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average price target of $189.76.

In other Jazz Pharmaceuticals news, CEO Bruce C. Cozadd sold 1,300 shares of Jazz Pharmaceuticals stock in a transaction on Friday, September 21st. The shares were sold at an average price of $164.36, for a total value of $213,668.00. Following the sale, the chief executive officer now directly owns 281,215 shares in the company, valued at approximately $46,220,497.40. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Patrick G. Enright sold 10,130 shares of Jazz Pharmaceuticals stock in a transaction on Thursday, September 6th. The shares were sold at an average price of $168.76, for a total transaction of $1,709,538.80. Following the completion of the sale, the director now owns 19,884 shares in the company, valued at $3,355,623.84. The disclosure for this sale can be found here. Insiders sold a total of 16,730 shares of company stock worth $2,773,011 over the last quarter. Company insiders own 3.90% of the company’s stock.

Hedge funds have recently modified their holdings of the business. Stratos Wealth Partners LTD. acquired a new stake in Jazz Pharmaceuticals in the 3rd quarter valued at $106,000. Riverhead Capital Management LLC acquired a new stake in Jazz Pharmaceuticals in the 3rd quarter valued at $113,000. Financial Enhancement Group LLC acquired a new stake in Jazz Pharmaceuticals in the 3rd quarter valued at $140,000. Tiverton Asset Management LLC acquired a new stake in Jazz Pharmaceuticals in the 2nd quarter valued at $198,000. Finally, Paloma Partners Management Co acquired a new stake in Jazz Pharmaceuticals in the 3rd quarter valued at $224,000. Hedge funds and other institutional investors own 92.30% of the company’s stock.

JAZZ opened at $151.20 on Monday. The firm has a market capitalization of $9.12 billion, a P/E ratio of 15.82, a P/E/G ratio of 0.91 and a beta of 1.06. Jazz Pharmaceuticals has a 12 month low of $130.15 and a 12 month high of $184.00. The company has a current ratio of 4.29, a quick ratio of 4.16 and a debt-to-equity ratio of 0.52.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology.

Read More: What is Cost of Capital?

Get a free copy of the Zacks research report on Jazz Pharmaceuticals (JAZZ)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply